Company intelligence / Profile preview

Vimelea Therapeutics

Gaithersburg, Maryland, United Statesvimelea-thera.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Vimelea is developing a novel class of small molecules inspired by the immunomodulatory protein ES‑62. These compounds selectively modulate myeloid and lymphoid immune cells implicated in cutaneous lupus erythematosus and other inflammatory diseases. The approach aims to reduce toxicity by targeting only unbalanced immune tissue. No human clinical data reported yet; all programs remain preclinical.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ES-62 small molecule analogues

Preclinical

Partnerships

Exclusive worldwide license with University of Strathclyde for the core technology/platform.

Beyond the preview

Go deeper on Vimelea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vimelea Therapeutics.

Explore the full profile